Introduction: The study aimed to investigate oncological outcomes of patients with concomitant bladder cancer (BC) and urethral carcinoma. Methods: This is a multicenter series of 110 patients (74 men, 36 women) diagnosed with urethral carcinoma at 10 referral centers between 1993 and 2012. Kaplan-Meier analysis was used to investigate the impact of BC on survival, and Cox regression multivariable analysis was performed to identify predictors of recurrence. Results: Synchronous BC was diagnosed in 13 (12%) patients, and the median follow-up was 21 months (interquartile range 4-48). Urethral cancers were of higher grade in patients with synchronous BC compared to patients with non-synchronous BC (p = 0.020). Patients with synchronous BC exhibited significantly inferior 3-year recurrence-free survival (RFS) compared to patients with non-synchronous BC (63.2 vs. 34.4%; p = 0.026). In multivariable analysis, inferior RFS was associated with clinically advanced nodal stage (p < 0.001), proximal tumor location (p < 0.001) and synchronous BC (p = 0.020). Conclusion: The synchronous presence of BC in patients diagnosed with urethral carcinoma has a significant adverse impact on RFS and should be an impetus for a multimodal approach.

Keywords:
Bladder cancer, Lymph node, Prognosis, Radical cystectomy, Risk factor, Survival, Urethra
1.
Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, et al; RARECARE Working Group: Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 2012;48:456-464.
2.
Swartz MA, Porter MP, Lin DW, Weiss NS: Incidence of primary urethral carcinoma in the United States. Urology 2006;68:1164-1168.
3.
Gakis G, Witjes JA, Compérat E, Cowan NC, De Santis M, Lebret T, et al: EAU guidelines on primary urethral carcinoma. Eur Urol 2013;64:823-830.
4.
Stenzl A, Draxl H, Posch B, Colleselli K, Falk M, Bartsch G: The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol 1995;153(3 pt 2):950-955.
5.
Sobin LH, Wittekind C: TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002.
6.
Shim JW, Cho KS, Choi YD, Lee DW, Han WS, et al: Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 2008;452:353-362.
7.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, et al: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012;61:854-855.
8.
Derksen JW, Visser O, de la Rivière GB, Meuleman EJ, Heldeweg EA, Lagerveld BW: Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol 2013;31:147-153.
9.
Rabbani F: Prognostic factors in male urethral cancer. Cancer 2011;117:2426-2434.
10.
Gakis G, Morgan TM, Efstathiou JA, Keegan KA, Mischinger J, Todenhoefer T, et al: Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol 2016;34:97-103.
11.
Gakis G, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Todenhofer T, et al: Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol 2015;26:1754-1759.
12.
Fahmy O, Scharpf M, Fend F, Stenzl A, Gakis G: Feasibility of penis-preserving surgery for urethral melanoma: proposal for a therapeutic algorithm. Clin Genitourin Cancer 2015;13:e411-e413.
13.
Hrbáček J, Macek P, Ali-El-Dein B, Thalmann GN, Stenzl A, Babjuk M, et al: Treatment and outcomes of urethral recurrence of urinary bladder cancer in women after radical cystectomy and orthotopic neobladder: a series of 12 cases. Urol Int 2015;94:45-49.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.